Figure 2.
Outcomes after uMRD attainment in the peripheral blood and bone marrow. (A) Landmark analysis of time to iwCLL progression stratified by MRD status at 24 months in the peripheral blood and bone marrow. Patients who progressed or came off study before 24 months (at which time >90% of uMRD attainment had occurred) were excluded. (B) Landmark analysis of overall survival stratified by MRD status at 24 months in the peripheral blood and bone marrow. Patients who died or came off study before 24 months (at which time >90% of uMRD attainment had occurred) were excluded.

Outcomes after uMRD attainment in the peripheral blood and bone marrow. (A) Landmark analysis of time to iwCLL progression stratified by MRD status at 24 months in the peripheral blood and bone marrow. Patients who progressed or came off study before 24 months (at which time >90% of uMRD attainment had occurred) were excluded. (B) Landmark analysis of overall survival stratified by MRD status at 24 months in the peripheral blood and bone marrow. Patients who died or came off study before 24 months (at which time >90% of uMRD attainment had occurred) were excluded.

Close Modal

or Create an Account

Close Modal
Close Modal